AI Article Synopsis
- The study explores the role of PSMG3-AS1, an oncogenic lncRNA, in lung adenocarcinoma (LUAD) and its relationship with patient survival.
- Patients with higher levels of PSMG3-AS1 had worse survival rates, while the expression of miR-449b-5p was found to be inversely related and downregulated in LUAD.
- Overexpression of miR-449b-5p can reduce PSMG3-AS1 levels and its effects on cell proliferation, suggesting it may serve as a potential therapeutic target to inhibit cancer growth in LUAD.
Article Abstract
Background: PSMG3-AS1 has been characterized as an oncogenic lncRNA in breast cancer, while its role in other cancers is unknown. This study investigated the role of PSMG3-AS1 in lung adenocarcinoma (LUAD).
Methods: This study included 64 LUAD patients (42 males and 22 females) who were enrolled between May 2012 and May 2014. RT-qPCR was used to evaluate the expression levels of lncRNA. Cell proliferation analysis was performed using CCK-8 kit.
Results: We found that upregulation of PSMG3-AS1 in LUAD predicted the poor survival of patients. MiR-449b-5p is downregulated in LUAD and the expression levels of LUAD were inversely correlated with the expression levels of PSMG3-AS1. MiR-449b-5p was predicted to target PSMG3-AS1, and overexpression of miR-449b-5p resulted in the downregulation of PSMG3-AS1 in LUAD cells. Cell proliferation analysis showed that overexpression of PSMG3-AS1 resulted in increased rate of cell proliferation. Overexpression of miR-449b-5p reduced the enhancing effects of PSMG3-AS1 on cell proliferation.
Conclusions: Therefore, miR-449b-5p may target PSMG3-AS1 in LUAD to suppress cancer cell proliferation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260832 | PMC |
| http://dx.doi.org/10.1186/s12890-020-01189-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!